GlycoMimetics Announces Publication of Phase 2 Data for Rivipansel in Sickle …

GAITHERSBURG, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the publication of results from a randomized, placebo-controlled Phase 2 investigational study evaluating the efficacy, safety and pharmacokinetics of rivipansel (GMI-1070) in patients with sickle cell disease hospitalized for a vaso-occlusive crisis (VOC). Study results were pre-published online by Blood,1 the journal …